Possible new Fate Therapeutics shares
FATEDilution
Known so far: no new shares from the prospectus covers read · shelf not limited by the baby-shelf rule · not yet read: warrants, converts.
Shelf room
- Room today not capped by the baby-shelf rule ($113M float, Jun 30, 2025)
How this is worked out
Shelf room on the S-3 of Apr 18, 2024: not limited by the baby-shelf rule, because the $113M public float stated as of Jun 30, 2025 is $75M or more. Sources: S-3 Apr 18, 2024, effective Apr 29, 2024 · public float, as of Jun 30, 2025.
What could become new Fate Therapeutics (FATE) shares: options and RSUs and an ATM program, each with the 10-Q, 10-K, S-3 or 424B filing it comes from.
Fate Therapeutics dilution ladder
Every source of new shares on record, from the filings that created it.
121.5M outstanding; up to 172.2M fully diluted, +42%
- Outstandingas of Nov 5, 2026 (S-3 cover) · Prospectus cover, shares outstanding before the offering121.5M
- At-the-market program$100.0M program, $8.0M sold424B5 Nov 5, 2026 · At-the-market prospectus supplementat $2.09, stated in the filing on Nov 4+44M
- +6.6M
Not stated in the filings we read: warrants, convertible notes.
Counts, sizes and prices as stated in each filing; the fully diluted count is arithmetic on them. Dollars become shares only at a price a filing states. Not advice.
Financing terms to know
None found in filings since Nov 5, 2026.
Each term is quoted from the exhibit it comes from; numbers are as stated in the filing. A flag describes a financing term. It is not investment advice.
Shares outstanding
122M
Feb 2025 to Oct 2026: from 115M to 122M.
From the share count on the cover of each 10-Q and 10-K, dated as each cover states.
Follow Fate Therapeutics
New shelves, offerings, 10-Qs and 10-Ks from FATE, explained in plain English when they reach EDGAR.
Watch FATE in the appData on this page was fetched . The filing on SEC.gov is the record.